0001193125-26-216769
SEC filingOperating and net losses narrowed modestly year-over-year, reflecting ongoing cost discipline, but cash used in operations remains substantial and management has concluded there is substantial doubt about the company’s ability to continue as a going concern.
Operating income and net income both improved year-over-year by 4.0% and 4.4%, respectively. These improvements reflect disciplined expense management amid portfolio prioritization, as noted in management commentary. Research and development activities continue to account for a significant portion of operating expenses, and costs include personnel, laboratory, and indirect facility and operating costs. While historical prioritizations have enabled reduced operating expenses, management cautions that expenses may increase over the longer term if clinical trials succeed or R&D efforts expand.
The company faces material funding risk: if sufficient capital cannot be raised when needed, business, financial condition, and results of operations will be materially and adversely affected, requiring modification of operational plans. Regulatory developments — including evolving guidance on international personal data transfers — add further uncertainty to planning assumptions, though they do not directly drive the current liquidity assessment.